Episode Details

Welcome to our latest TDR exclusive! In this episode with Doug Drysdale, CEO of Cybin we get into their groundbreaking developments in mental healthcare, including FDA clearance for a Phase 2a study of CYB004 in Generalized Anxiety Disorder, the positive impact of CYB003 on MADRS scores, and the future of psychedelic therapies in the industry. Stay tuned for exclusive insights into the evolving landscape of mental health treatments and Cybin's mission to revolutionize the field. Guest: Doug Drysdale, CEO of Cybin 🔥 Join us for an in-depth interview with Cybin Inc., where we explore groundbreaking developments in mental healthcare and psychedelic treatments! 🧠 Learn about Cybin's FDA clearance for the Phase 2a study of CYB004 in Generalized Anxiety Disorder (GAD) and its mission to revolutionize mental healthcare. 💊 Discover the positive impact of CYB003 on MADRS scores, its significance in the market, and safety considerations. 🌌 Gain insights into Phase 1 studies of proprietary deuterated DMT molecules CYB004 and SPL028, and their role in safer and more effective mental health treatments. 💡 Discuss industry inflection points, potential legislative changes, and the impact of FDA decisions on psychedelic therapies. 📅 Get an exclusive timeline for CYB004's Phase 2a study in GAD and other near-term catalysts in 2024! Stay tuned for insights into the future of mental healthcare and Cybin Inc.'s exciting developments! Subscribe now! 🌟 #MentalHealth #PsychedelicTherapies #CybinInc #FDAApproval #Innovation